共 50 条
- [31] Real-World effectiveness and safety of fremanezumab in migraine: 3rd interim analysis of the pan-european PEARL studyJOURNAL OF HEADACHE AND PAIN, 2024, 25Ashina, M.Mitsikostas, D. D.Amin, F. MohammadKokturk, P.Schankin, C. J.Sahin, G.Pozo-Rosich, P.Dorman, P.Nezadal, T.Poole, A. ChristineMartins, I. PavaoSumelahti, M. L.Campos, V. RamirezNing, X.Lyras, L.Tassorelli, C.
- [32] Long-term real-world evidence of SB5 (adalimumab biosimilar) treatment in patients with moderate-to-severe psoriasis from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR)JOURNAL OF DERMATOLOGICAL TREATMENT, 2024, 35 (01)Girolomoni, GiampieroFeldman, Steven R.Egeberg, AlexanderPuig, LuisJung, JinahJung, HojungLee, Younju
- [33] Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn's disease: 3-year results from a real-world studyINTESTINAL RESEARCH, 2021, 19 (04) : 408 - 418Hisamatsu, TadakazuSuzuki, YasuoKobayashi, MarikoHagiwara, TakashiKawaberi, TakeshiOgata, HaruhikoMatsui, ToshiyukiWatanabe, MamoruHibi, Toshifumi
- [34] Benefit Study: Results of Interim Analysis of a Pan-European Observational Study to Evaluate Real-World Effectiveness of SB4 Following Transition from Originator Etanercept (ETN) in Patients with Rheumatoid Arthritis (RA) or Axial Spondyloarthritis (AxSpA)ARTHRITIS & RHEUMATOLOGY, 2018, 70Krueger, KlausSelmi, CarloCantagrel, AlainAbad, Miguel A.Freudensprung, UlrichRezk, Mourad FaroukAddison, Janet
- [35] Impact of Anti-Drug Antibodies on Efficacy and Safety up to Week 24 from A Phase III Study Comparing SB5 (An Adalimumab Biosimilar) with Reference Adalimumab in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate TherapyJOURNAL OF RHEUMATOLOGY, 2017, 44 (06) : 878 - 878Genovese, MarkWeinblatt, MichaelKeystone, EdwardBaranauskaite, AstaCheong, Soo-YeonGhil, Jeehoon
- [36] The first interim analysis of Italian patients enrolled in the real-world, Pan-European, prospective, observational, phase 4 PEARL study of fremanezumab effectivenessNEUROLOGICAL SCIENCES, 2024, 45 (05) : 2353 - 2363Tassorelli, CristinaBarbanti, PieroFinocchi, CinziaGeppetti, PierangeloKokturk, PinarRusso, AntonioSacco, SimonaCepparulo, Mario
- [37] Real-world safety and effectiveness of adalimumab in patients with pyoderma gangrenosum: Interim analysis of a post-marketing observational study in JapanJOURNAL OF DERMATOLOGY, 2025, 52 (02): : 270 - 280Yamamoto, ToshiyukiYamanaka, KeiichiYamasaki, KenshiIsaji, HisaakiMatsubara, NaokoHozawa, HiroyukiKawakami, Tamihiro
- [38] IMPACT OF ANTI-DRUG ANTIBODIES ON EFFICACY AND SAFETY UP TO WEEK 24 FROM A PHASE III STUDY COMPARING SB5 (AN ADALIMUMAB BIOSIMILAR) WITH ADALIMUMAB REFERENCE PRODUCT IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPYANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 234 - 234Genovese, M. C.Weinblatt, M.Keystone, E.Baranauskaite, A.Cheong, S. Y.Ghil, J.
- [39] Real-world effectiveness of fremanezumab for the preventive treatment of migraine: Interim analysis of the pan-European, prospective, observational, phase 4 PEARL studyCEPHALALGIA, 2023, 43 (11)Ashina, MessoudMitsikostas, Dimos D.Amin, Faisal MohammadKokturk, PinarSchankin, Christoph J.Sahin, GurdalPozo-Rosich, PatriciaDorman, Paul J.Nezadal, TomasPoole, Anne ChristineMartins, Isabel PavaoSumelahti, Marja-LiisaCampos, Verena RamirezAhn, Andrew H.Lyras, LeonidasTassorelli, Cristina
- [40] IBD Reference and Biosimilar adalimumab CroSS over Study (iBaSS): a mixed methods clinical trial of patients transitioning between originator and biosimilar adalimumab. Qualitative findings from an interim analysis presenting the patient perspectiveJOURNAL OF CROHNS & COLITIS, 2021, 15 : S537 - S538Young, D.Latter, S.Harvey, J.Addison, J.Freudensprung, J.Cummings, F.